Teva announces revocation two UK Fosamax patents
The UK High Court of Justice Chancery Division Patents Court has ruled in favor of Israel’s Teva and two other companies that two Merck patents covering Fosamax are invalid. Alendronate Sodium Tablets are the generic equivalent of Merck's Fosamax Tablets.
The product is indicated for the treatment and prevention of osteoporosis in postmenopausal women and the treatment of Paget's disease. Annual branded sales of Fosamax in the UK are approximately ₤44 million. Teva does not expect to generate sales of this product in the UK. prior to 2004 due to regulatory procedures.
Teva Pharmaceutical Industries is among the top 35 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. Over 80 percent of Teva's sales are in North America and Europe. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. — (menareport.com)
© 2003 Mena Report (www.menareport.com)